266 related articles for article (PubMed ID: 21734532)
1. Liraglutide for the treatment of type 2 diabetes: a clinical update.
Peters KR
Am J Ther; 2013; 20(2):178-88. PubMed ID: 21734532
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Ann Pharmacother; 2009 Sep; 43(9):1433-44. PubMed ID: 19638470
[TBL] [Abstract][Full Text] [Related]
3. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
4. Review of the therapeutic uses of liraglutide.
Ryan GJ; Foster KT; Jobe LJ
Clin Ther; 2011 Jul; 33(7):793-811. PubMed ID: 21741090
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
6. Potential of liraglutide in the treatment of patients with type 2 diabetes.
Deacon CF
Vasc Health Risk Manag; 2009; 5(1):199-211. PubMed ID: 19436648
[TBL] [Abstract][Full Text] [Related]
7. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Trujillo JM; Nuffer W
Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
[TBL] [Abstract][Full Text] [Related]
8. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
Tzefos M; Olin JL
Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
[TBL] [Abstract][Full Text] [Related]
11. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
13. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL; Baker DE; Setter SM; Keith Campbell R
Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
[TBL] [Abstract][Full Text] [Related]
14. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
Mateos JL; Wajchenberg BL
Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
Bode BW; Brett J; Falahati A; Pratley RE
Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
[TBL] [Abstract][Full Text] [Related]
18. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
Nauck M; Marre M
Postgrad Med; 2009 May; 121(3):5-15. PubMed ID: 19491535
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
